Published in Proc Am Thorac Soc on January 01, 2005
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene (2010) 1.70
Molecular imaging of pulmonary cancer and inflammation. Proc Am Thorac Soc (2009) 0.76
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med (2003) 3.88
Regulation of human thymidine kinase during the cell cycle. J Biol Chem (1988) 2.67
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res (2003) 2.46
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol (2003) 2.35
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology (1994) 2.28
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med (2004) 2.22
Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med (1997) 2.14
Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol (1999) 1.95
Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med (1996) 1.91
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med (2005) 1.81
Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol (1998) 1.64
[18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging (2004) 1.61
The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys (2005) 1.43
Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res (2005) 1.43
Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med (1999) 1.41
Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol (2004) 1.33
PET imaging of cellular proliferation. Radiol Clin North Am (2005) 1.29
The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist (2004) 1.27
Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med (1998) 1.21
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol (2004) 1.21
Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg (1994) 1.09
Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging (2004) 1.05
Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am (2005) 1.03
18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med (2004) 1.01
18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med (2005) 0.99
Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging (2004) 0.97
Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med (2000) 0.92
FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden. Acta Oncol (2003) 0.89
Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol (2004) 0.87
[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovasc Surg (2004) 0.85
A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med (1996) 0.85
Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med (1998) 0.84
Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest (2004) 0.84
Clinical evaluation and staging of patients who have lung cancer. Hematol Oncol Clin North Am (2005) 0.83
Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg (1999) 0.81
Increased standardized uptake value in the primary lesion predicts nodal or distant metastases at presentation in lung cancer. Clin Lung Cancer (2005) 0.77
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med (2006) 3.20
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg (2004) 2.65
The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer (2007) 2.30
Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA (2007) 2.22
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys (2009) 2.05
Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol (2002) 1.83
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.82
Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys (2004) 1.70
Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol (2011) 1.67
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J Surg (2010) 1.57
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol (2010) 1.55
18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med (2011) 1.45
Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys (2005) 1.39
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol (2009) 1.38
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum (2008) 1.35
Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer. Eur J Nucl Med Mol Imaging (2013) 1.26
Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol (2004) 1.21
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer (2005) 1.20
Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer (2010) 1.19
An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med (2008) 1.18
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol (2004) 1.15
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med (2003) 1.14
Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology (2003) 1.14
Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol (2008) 1.12
The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg (2007) 1.11
Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol (2003) 1.10
Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol (2007) 1.05
Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging (2005) 1.05
F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol (2005) 1.05
Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol (2004) 1.04
Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys (2007) 1.02
Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med (2003) 1.00
Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys (2012) 0.99
Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys (2004) 0.99
FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys (2006) 0.97
Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol (2002) 0.96
Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol (2002) 0.96
Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol (2008) 0.95
Correlation of severity of FDG-PET hypometabolism and interictal regional delta slowing in temporal lobe epilepsy. Epilepsia (2005) 0.94
Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys (2011) 0.94
Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol (2007) 0.92
The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med (2009) 0.92
FDG uptake in colonic villous adenomas. Ann Nucl Med (2005) 0.92
Clinical-pathologic conference in general thoracic surgery: Cardiac lymphoma. J Thorac Cardiovasc Surg (2005) 0.91
Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys (2003) 0.91
Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J Nucl Med (2004) 0.90
FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys (2003) 0.89
PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys (2003) 0.87
FDG-PET Evaluation of Carcinoma of the Cervix. Clin Positron Imaging (1999) 0.87
FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol (2012) 0.87
Imaging tumor phenotype: 1 plus 1 is more than 2. J Nucl Med (2009) 0.86
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol (2013) 0.84
Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer (2009) 0.84
Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET. Int J Radiat Oncol Biol Phys (2010) 0.83
Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. NMR Biomed (2014) 0.83
Novel methods and tracers for breast cancer imaging. Semin Nucl Med (2013) 0.81
Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix. J Magn Reson Imaging (2012) 0.81
FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys (2005) 0.79
PET Radiotracers for Imaging the Proliferative Status of Solid Tumors. PET Clin (2009) 0.78
Oncologic PET/CT: current status and controversies. Eur Radiol (2005) 0.78
Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J Hepatobiliary Pancreat Surg (2008) 0.78
Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol (2010) 0.77
Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer. J Surg Oncol (2010) 0.77
A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. Cancer Med (2014) 0.77
PET/MRI for the body imager: abdominal and pelvic oncologic applications. Abdom Imaging (2015) 0.75